Logo image of BDSI

BIODELIVERY SCIENCES INTL (BDSI) Stock Price, Quote, News and Overview

NASDAQ:BDSI - Nasdaq - Common Stock

5.59  0 (-0.09%)

After market: 5.6 +0.01 (+0.18%)

BDSI Quote, Performance and Key Statistics

BIODELIVERY SCIENCES INTL

NASDAQ:BDSI (3/22/2022, 8:00:02 PM)

After market: 5.6 +0.01 (+0.18%)

5.59

0 (-0.09%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High5.62
52 Week Low2.5
Market Cap552.29M
Shares98.80M
Float90.98M
Yearly DividendN/A
Dividend YieldN/A
PE6.73
Fwd PE15.84
Earnings (Next)05-04 2022-05-04
IPO06-25 2002-06-25


BDSI short term performance overview.The bars show the price performance of BDSI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

BDSI long term performance overview.The bars show the price performance of BDSI in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30 40 50

The current stock price of BDSI is 5.59 null. In the past month the price increased by 0.72%. In the past year, price increased by 53.15%.

BIODELIVERY SCIENCES INTL / BDSI Daily stock chart

BDSI Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 67.21 829.40B
NVO NOVO-NORDISK A/S-SPONS ADR 27.44 390.99B
JNJ JOHNSON & JOHNSON 16.25 390.76B
AZN ASTRAZENECA PLC-SPONS ADR 20.56 230.17B
MRK MERCK & CO. INC. 11.71 226.40B
NVS NOVARTIS AG-SPONSORED ADR 13.77 215.98B
PFE PFIZER INC 8.46 149.04B
SNY SANOFI-ADR 13.58 136.54B
BMY BRISTOL-MYERS SQUIBB CO 48.97 113.23B
GSK GSK PLC-SPON ADR 7.78 74.77B
ZTS ZOETIS INC 27.1 72.39B
TAK TAKEDA PHARMACEUTIC-SP ADR 31.95 44.58B

About BDSI

Company Profile

BDSI logo image BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.

Company Info

BIODELIVERY SCIENCES INTL

4131 Parklake Ave Ste 225

Raleigh NORTH CAROLINA 27612 US

CEO: Jeffrey Bailey

Employees: 200

Company Website: https://www.bdsi.com/

Phone: 19195829050.0

BIODELIVERY SCIENCES INTL / BDSI FAQ

What is the stock price of BIODELIVERY SCIENCES INTL today?

The current stock price of BDSI is 5.59 null. The price decreased by -0.09% in the last trading session.


What is the ticker symbol for BIODELIVERY SCIENCES INTL stock?

The exchange symbol of BIODELIVERY SCIENCES INTL is BDSI and it is listed on the Nasdaq exchange.


On which exchange is BDSI stock listed?

BDSI stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BIODELIVERY SCIENCES INTL stock?

13 analysts have analysed BDSI and the average price target is 5.48 null. This implies a price decrease of -1.88% is expected in the next year compared to the current price of 5.59. Check the BIODELIVERY SCIENCES INTL stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BIODELIVERY SCIENCES INTL worth?

BIODELIVERY SCIENCES INTL (BDSI) has a market capitalization of 552.29M null. This makes BDSI a Small Cap stock.


How many employees does BIODELIVERY SCIENCES INTL have?

BIODELIVERY SCIENCES INTL (BDSI) currently has 200 employees.


What are the support and resistance levels for BIODELIVERY SCIENCES INTL (BDSI) stock?

BIODELIVERY SCIENCES INTL (BDSI) has a support level at 5.58 and a resistance level at 5.6. Check the full technical report for a detailed analysis of BDSI support and resistance levels.


Is BIODELIVERY SCIENCES INTL (BDSI) expected to grow?

The Revenue of BIODELIVERY SCIENCES INTL (BDSI) is expected to grow by 22.27% in the next year. Check the estimates tab for more information on the BDSI EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIODELIVERY SCIENCES INTL (BDSI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIODELIVERY SCIENCES INTL (BDSI) stock pay dividends?

BDSI does not pay a dividend.


When does BIODELIVERY SCIENCES INTL (BDSI) report earnings?

BIODELIVERY SCIENCES INTL (BDSI) will report earnings on 2022-05-04.


What is the Price/Earnings (PE) ratio of BIODELIVERY SCIENCES INTL (BDSI)?

The PE ratio for BIODELIVERY SCIENCES INTL (BDSI) is 6.73. This is based on the reported non-GAAP earnings per share of 0.83 and the current share price of 5.59 null. Check the full fundamental report for a full analysis of the valuation metrics for BDSI.


BDSI Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to BDSI. When comparing the yearly performance of all stocks, BDSI is one of the better performing stocks in the market, outperforming 97.69% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

BDSI Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to BDSI. While BDSI has a great profitability rating, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BDSI Financial Highlights

Over the last trailing twelve months BDSI reported a non-GAAP Earnings per Share(EPS) of 0.83. The EPS increased by 232% compared to the year before.


Industry RankSector Rank
PM (TTM) 50.91%
ROA 26.14%
ROE 45.18%
Debt/Equity 0.29
Chartmill High Growth Momentum
EPS Q2Q%520%
Sales Q2Q%2.33%
EPS 1Y (TTM)232%
Revenue 1Y (TTM)6.54%

BDSI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 74% to BDSI. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of -57.48% and a revenue growth 22.27% for BDSI


Ownership
Inst Owners0.12%
Ins Owners2.45%
Short Float %N/A
Short RatioN/A
Analysts
Analysts73.85
Price Target5.48 (-1.97%)
EPS Next Y-57.48%
Revenue Next Year22.27%